Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156380 | 0.89 | VDR (0.50) | VDRALOX5PKMMAOBBCL2 | |
| SCHEMBL6154549 | 0.86 | VDR (0.49) | VDRALOX5PKMMAOBAPP | |
| SCHEMBL6155566 | 0.85 | VDR (0.48) | VDRALOX5PKMMAOBNR4A2 | |
| SCHEMBL6154719 | 0.82 | VDR (0.48) | VDRALOX5PKMMAOBAPP | |
| SCHEMBL4169952 | 0.82 | APP (0.40) | ALOX5PKMMAOBAPPBCL2 | |
| SCHEMBL2785501 | 0.80 | VDR (0.49) | VDRALOX5 | |
| SCHEMBL6158285 | 0.80 | VDR (0.49) | VDRPKMMAOBAPP | |
| SCHEMBL6155122 | 0.79 | VDR (0.48) | VDR | |
| SCHEMBL6155129 | 0.79 | VDR (0.48) | VDRALOX5APPBCL2 | |
| SCHEMBL6155609 | 0.78 | VDR (0.48) | VDRALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1952808-A2 | Composition in the form of a spray comprising calcitriol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-08-06 | — | — | EP | disclosed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | disclosed |
| US-20070135379-A1 | Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-06-14 | — | — | US | disclosed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1686972-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | Galderma Research & Development, S.N.C. (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005053666-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | WO | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135379-A1 | Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle | IDUA, ARSA, STS | VDR 3900/4885ALOX5 3356/4885PKM 881/4885 |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | CYP24A1, CYP2R1, VDR | VDR 3/4885ALOX5 153/4885PKM 3787/4885 |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | CYP19A1, CYP17A1, CYP51A1 | VDR 158/4885ALOX5 85/4885PKM 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.